## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `retatrutide-gut`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/retatrutide-gut/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/retatrutide-gut/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/retatrutide-gut/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/retatrutide-gut/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/retatrutide-gut/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/retatrutide-gut/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `retatrutide-gut` v2 · content_hash `ce72609df5d2e5c2…` · thread_head genesis · 23 DIVs
- **thesis (c1):** Phase 2 trial showed up to 24.2% weight loss at 48 weeks on highest retatrutide dose vs 2.1% placebo.
  - c2 [human/active] GI adverse events (nausea, diarrhea, constipation) were most common and dose-related in retatrutide trials.
  - c4 [human/active] Phase 3 TRIUMPH-1 reported 28.3% average weight loss at 80 weeks on 12 mg retatrutide.
  - c3 [preclinical/active] GLP-1 agonist treatment in obese mice produced shifts in gut microbiome composition linked to reduced caloric intake.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/retatrutide-gut/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/retatrutide-gut/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `retatrutide-gut`
- **title:** Retatrutide for Gut: Evidence-Graded Look at Metabolic Load Reduction
- **url:** https://miscsubjects.com/a/retatrutide-gut
- **register:** source_ledger
- **updated:** 2026-07-17T02:41:17.406Z
- **tags:** peptide, matrix

## Body

## What's breaking down

Excess body weight places ongoing mechanical and metabolic stress on multiple systems, including the gut. When body mass increases, intra-abdominal pressure rises, which can alter gut motility, increase reflux risk, and compound issues with digestion and nutrient absorption over time. This creates a cycle where degeneration (sustained load and inflammation) outpaces natural repair processes in the gastrointestinal tract. Retatrutide targets one upstream layer—body weight—through GLP-1, GIP, and glucagon receptor agonism, studied primarily for weight reduction rather than direct gut tissue repair.

## Why Retatrutide might help you

1. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia. The same excess mass increases intra-abdominal pressure that can impair gut motility and heighten mechanical strain on the digestive tract.

2. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration or direct gut lining repair.

3. **Therefore for you:** If excess weight forms part of your gut-related load, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks symptoms or repairs gut tissue directly.

## How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.
- **Retatrutide** → metabolic load / body weight

## What the evidence actually shows

Human trials of retatrutide (phase 2, n=338 adults with obesity) showed dose-dependent weight loss reaching up to 24.2% at 48 weeks on the highest dose versus 2.1% on placebo (human tier). Gastrointestinal adverse events were the most common, dose-related, and mostly mild to moderate; these included nausea, diarrhea, and constipation (human tier). Phase 3 data (TRIUMPH-1) reported average losses of 28.3% body weight at 80 weeks on 12 mg, with similar GI event patterns (human tier). No dedicated human trials examined direct gut repair or microbiome restoration with retatrutide.

Preclinical work on GLP-1 agonists (including analogs) in diet-induced obese mice showed shifts in gut microbiome composition alongside weight loss and improved glucose handling (preclinical tier). One mouse study found discrete changes in low-abundance bacterial species after liraglutide or dual GLP-1/GLP-2 agonism, linked to caloric intake reduction rather than direct microbial targeting (preclinical tier). Retatrutide-specific animal data on gastric emptying exist but remain limited to metabolic endpoints (preclinical tier).

Anecdotal reports on social platforms describe variable gut motility changes, bloating, or reflux during retatrutide use, sometimes alongside weight loss; these remain individual experiences without controlled measurement (anecdotal tier).

## What scientists say

Researchers note that weight loss from triple agonists like retatrutide reduces overall metabolic burden, which may indirectly ease gut strain through lower intra-abdominal pressure (mechanistic tier). GI side effects are attributed to delayed gastric emptying and central appetite effects common to the class (human tier from trials). Hypotheses link GLP-1 agonism to microbiome alterations via reduced intake or motility changes, but directionality and causality require further study (speculative tier).

## What people say on Reddit

Users frequently report initial nausea or slowed digestion that often improves with dose titration or time; some note better satiety and indirect gut comfort after substantial weight loss. Others describe persistent bloating or constipation requiring dietary adjustments. All accounts are self-reported and unverified (anecdotal tier).

## What people say on X

Posts highlight retatrutide’s weight-loss potency alongside mentions of reflux or motility shifts; several users pair it with gut-supportive practices. Comments remain personal observations without clinical confirmation (anecdotal tier).

## What we do not know

No human data exist on retatrutide’s long-term impact on gut barrier function, microbiome diversity, or specific gastrointestinal conditions independent of weight change. The relative contribution of direct receptor effects versus secondary weight loss to any gut changes is unclear. Large phase 3 cardiovascular outcome trials are ongoing but focus on weight and cardiac endpoints rather than gut-specific outcomes.

## Safety and limits

Common adverse events in trials were gastrointestinal and dose-dependent; most resolved or lessened with slower titration (human tier). Heart-rate increases were observed but tended to peak and decline. Retatrutide remains investigational; trial data do not establish safety or efficacy for primary gut repair. Evidence separates cleanly into substantial human weight-loss results, limited preclinical microbiome observations, and uncontrolled anecdotes.

## Claims (4)

- **c2** [human w=0.8] GI adverse events (nausea, diarrhea, constipation) were most common and dose-related in retatrutide trials.
  - who_claims: grok/grok-4.3
  - sources: s9, s10
- **c4** [human w=0.8] Phase 3 TRIUMPH-1 reported 28.3% average weight loss at 80 weeks on 12 mg retatrutide.
  - who_claims: grok/grok-4.3
  - sources: s10
- **c3** [preclinical w=0.5] GLP-1 agonist treatment in obese mice produced shifts in gut microbiome composition linked to reduced caloric intake.
  - who_claims: grok/grok-4.3
  - sources: s3
- **c1** [human w=0.8] Phase 2 trial showed up to 24.2% weight loss at 48 weeks on highest retatrutide dose vs 2.1% placebo.
  - who_claims: grok/grok-4.3
  - sources: s9

## Voxel graph (4 atoms · 9 edges)
- full graph: https://miscsubjects.com/api/articles/retatrutide-gut/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (3)
- chain valid: yes · head: `a6d0a8ef1bbfe608`

### s3 · pubmed · ok
- title: Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
- url: https://www.nature.com/articles/s41598-019-52103-x
- summary: Mouse study on GLP-1 effects on microbiome.
- quote: Compared to baseline, DIO mice assumed phylogenetically similar gut bacterial compositional changes following liraglutide and GUB09-145 treatment, characterized by discrete shifts in low-abundant species
- claim_ids: c3
- hash: `a6d0a8ef1bbfe608`

### s9 · pubmed · http_403
- title: Triple–Hormone-Receptor Agonist Retatrutide for Obesity
- url: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
- summary: Phase 2 trial results detailing dose-dependent weight loss and GI adverse events.
- quote: At 48 weeks, the least-squares mean percentage change in the retatrutide groups was −8.7% in the 1-mg group, −17.1% in the combined 4-mg group, −22.8% in the combined 8-mg group, and −24.2% in the 12-mg group, as compared with −2.1% in the placebo group.
- claim_ids: c1, c2
- hash: `c74d475067414391`

### s10 · news · ok
- title: Lilly's triple agonist, retatrutide, delivered powerful weight loss
- url: https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
- summary: Phase 3 topline weight-loss data.
- quote: In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks
- claim_ids: c2, c4
- hash: `bbf208cc52d91f3d`

## Provenance (2 model passes)
- chain valid: yes · head: `d3967599856feb62`

- write · grok/grok-4.3 · 2026-06-30T00:59 · hash `e21101481545`
- voxel_divide · owner · 2026-07-17T02:41 · hash `d3967599856f`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/retatrutide-gut/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/retatrutide-gut/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"retatrutide-gut","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest retatrutide-gut|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim retatrutide-gut|tier|assertion`
- **iMessage ask:** `retatrutide-gut|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `retatrutide-gut`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/retatrutide-gut/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/retatrutide-gut/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*